Topical decongestants in combination therapy of acute respiratory infections in children (a literature review)
https://doi.org/10.21518/2079-701X-2015-14-26-29
Abstract
Acute respiratory infections are a serious public health problem due to very high incidence and a serious economic burden. They account for about 90% of all infectious diseases and 70% of childhood diseases. About ¼ of the total health care costs are associated with the diagnosis and treatment of acute respiratory infections. Though the disease is often moderate and has a good prognosis, it can significantly affect the well-being of children and interfere with their activities of daily living. [1-2]. In most cases (about 95%), acute respiratory infections are caused by a variety of viruses - influenza and parainfluenza, respiratory syncytial, adenovirus, rhinovirus, coronavirus, enterovirus, with the total number of etiological serotypes exceeding180. [1] The significant incidence of acute respiratory infection (ARI) is conditioned by several factors: high susceptibility of children (especially young children), variety of pathogens, as well as air-borne transmission and high contagiousness. [3]
About the Authors
A. B. Мalakhov
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
I. S. Shatalina
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
I. A. Dronov
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
M. A. Malakhov-kapanadze
Kolomna Central District Hospital
Russian Federation
Russian Federation
A. R. Denisova
First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. Острые респираторные инфекции у детей: лечение и профилактика. Научно-практическая программа. М.: Международный фонд охраны здоровья матери и ребенка, 2002. 72 с.
2. Учайкин В.Ф. Диагностика, лечение и профилактика гриппа и острых респираторных заболеваний у детей. Пособие для врачей. М., 2001. 14 с.
3. Комплексный подход к лечению и профилактике острых респираторных вирусных инфекций у детей: Практическое руководство для врачей. Под ред. проф. Н.А. Геппе, проф. А.Б. Малахова. М., 2012. 47 с.
4. Fokkens WJ, Lund VJ, MuLLoLJ et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2012. Rhinol Suppl. 2012. 23: 1-298.
5. Заплатников А.Л. Топические деконгестанты в педиатрической практике: безопасность и клиническая эффективность. Педиатрия, 2006, 6: 69-75.
6. Карпова Е.П., Тулупов Д.А. К вопросу о безопасности и эффективности назальных сосудосуживающих препаратов в педиатрической практике. Вопросы практической педиатрии, 2010, 5: 65-69.
7. Рязанцев С.В. Современные деконгестанты в комплексной терапии острых и хронических заболеваний ЛОР-органов. Российская оториноларингология, 2005, 6: 71-74.
8. Дронов И.А., Малахов А.Б. Возможности повышения эффективности и безопасности применения назальных деконгестантов у детей. Эффективная фармакотерапия, 2013, 39: 4-8.
9. Eccles R, Eriksson M, Garreffa S, Chen SC. The nasal decongestant effect of xylometazoline in the common cold. Am. J. Rhinol., 2008, 22, 5: 491-496.
10. Caenen M, Hamels K, Deron P, Clement P. Comparison of decongestive capacity of xylometazoline and pseudoephedrine with rhino-manometry and MRI. Rhinology, 2005, 43, 3: 205-209.
11. Eskiizmir G, Hirgin Z, Ozyurt B, Unlu H. A comparative analysis of the decongestive effect of oxymetazoline and xylometazoline in healthy subjects. Eur. J. Clin. Pharmacol. 2011, 67, 1: 19-23.
12. Jensen JH, Leth N, Bonding P. Topical application of decongestant in dysfunction of the Eustachian tube: a randomized, double-blind,placebo-controlled trial. Clin. Otolaryngol. Allied. Sci., 1990, 15, 3: 197-201.
13. Westerveld GJ, Voss HP, van der Hee RM et al. Inhibition of nitric oxide synthase by nasal decongestants. Eur. Respir. J. 2000, 16, 3: 437444.
14. Serrano C, Valero A, Bartra J et al. Effects on nasal nitric oxide production of 2 mechanisms of vasoconstriction. J. Investig. Allergol. Clin. Immunol., 2007, 17, 5: 337-340.
15. Petruson B, Hansson HA. Function and structure of the nasal mucosa after 6 weeks' use of nose-drops. Acta Otolaryngol. 1982. 94, 5-6: 563-569.
16. Pradalier A. Pharmacological and clinical eval-utation of nasal obstruction: application to xylometazoline. Therapie 2006, 61, 1: 3-11.
17. Deitmer T, Scheffler R. The effect of different preparations of nasal decongestants on ciliary beat frequency in vitro. Rhinology, 1993, 31, 4: 151-153.
18. Mickenhagen A, Siefer O, Neugebauer P Stennert E. The influence of different alpha-sympathomimetic drugs and benzalkonium-chlorid on the ciliary beat frequency of in vitro cultured human nasal mucosa cells. Laryngorhinootologie 2008, 87, 1: 30-38.
19. Riechelmann H, Deutschle T, Stuhlmiller A et al. Nasal toxicity of benzalkonium chloride. Am. J. Rhinol. 2004 18, 5: 291-299.
20. Dorn M, Hofmann W, Knick E. Tolerance and effectiveness of oxymetazoline and xylo-metazoline in treatment of acute rhinitis. HNO, 2003, 51, 10: 794-799.
21. Laurent TC. Biochemistry of hyaluronan. Acta Otolaryngol. Suppl. 1987. 442: 7-24.
22. Macchi A, Castelnuovo P, Terranova P, Digilio E. Effects of sodium hyaluronate in children with recurrent upper respiratory tract infections: results of a randomised controlled study. Int. J. Immunopathol. Pharmacol. 2013. 26, 1: 127-135.
23. Castellano F, Mautone G. Decongestant activity of a new formulation of xylometazoline nasal spray: a double-blind, randomized versus placebo and reference drugs controlled, dose-effect study. Drugs Exp. Clin. Res. 2002, 28, 1: 27-35.
Review
For citations:
Мalakhov AB, Shatalina IS, Dronov IA, Malakhov-kapanadze MA, Denisova AR. Topical decongestants in combination therapy of acute respiratory infections in children (a literature review). Meditsinskiy sovet = Medical Council. 2015;(14):26-29. (In Russ.) https://doi.org/10.21518/2079-701X-2015-14-26-29
Views:
676
Email this article 